MS News That Caught My Eye Last Week: COVID-19 Website, Testing MS Progression, RIS, Alternative Treatments
MSAA Opens ‘COVID-19 and MS Pathfinder’ Online Informative Platform Information about MS and COVID-19 is dynamic and regularly changing.
Articles by Ed Tobias
Can We Be Taught How to Avoid an MS Fall?
I’d just gotten out of bed the other morning and was headed to the bathroom using just one cane when…
MS News That Caught My Eye Last Week: Epstein-Barr Link, Cannabis Study, Relapses and Disability
B-Cells Infected by Epstein-Barr Virus Linked to MS Relapse Risk in Study I usually steer clear of mouse studies.
It’s Disability Pride Month — But Not for Me
July is Disability Pride Month. Now, don’t slam me right away for writing this, but I don’t think we need…
MS News That Caught My Eye Last Week: Wearable Sensors, COVID-19, Tecfidera
PROTXX, University of Alberta Collaborate to Develop Remote Healthcare Platform for MS Patients As more and more neurologists turn…
MS News That Caught My Eye Last Week: Mayzent, Hookworm Therapy, Walking and Falling, ADS-5102
NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS Currently, the only disease-modifying therapy approved for…
Updating the Shifting MS-COVID-19 Treatment Equation
It’s been a few weeks since I’ve written about the impact that COVID-19 is having on people with MS.
MS News That Caught My Eye Last Week: Gilenya and COVID-19, Depression, Switching from Tysabri
Gilenya May Help Control Severe Respiratory Disease in COVID-19 This story caught my eye, but not because of the…
My Review of 2 New MS Apps: icompanion and BelongMS
A couple new mobile apps for people with MS have caught my attention. Icompanion is among the best symptom…
MS News That Caught My Eye Last Week: Myelin, Mavenclad, Online Stress Relief, Rehab Aids
Note: A story mentioned in this column, “Prime Signs Agreement With…
I’m Tired Again, and I’m Sure You’ve Been There
Are you tired? Really tired? Me, too. Most of us with multiple sclerosis are. How many is most? A small…
MS News that Caught My Eye Last Week: Ofatumumab, Zeposia, Early Symptoms, New App
FDA Extends Review of Ofatumumab for Relapsing MS to September The U.S. Food and Drug Administration (FDA) was expected…
Another Medication, Zeposia, Joins the MS Treatment Arsenal
By my unofficial count, disease-modifying therapy No. 19 has just become available to people with multiple sclerosis in the U.S.
MS News that Caught My Eye Last Week: Pollution and MS, ATA188, Ofatumumab, Zeposia
Air Pollution of Urban Life Raises MS Risk, Study from Italy Suggests I grew up in New York City.
Am I Having an MS Relapse?
As I sit down to write this week’s column, it’s hard for me to concentrate. I’d planned to write about…
MS News that Caught My Eye Last Week: Vascular Disease, Glatopa vs. Copaxone, Exercise Tips, MS App
Higher Risk of Vascular Disease Among MS Patients in the UK, Population-based Study Reveals You’d think that people with…
Giving My Laptop the Weekend Off
My favorite line in the “Downton Abbey” TV series, uttered by the dowager played by Maggie Smith, is “What’s a…
MS News that Caught My Eye Last Week: COVID-19 Data, Epstein-Barr, PoNS Device, Mindfulness
COVID-19 May Not Be Severe in MS Patients, Early Data from Italy Suggest Keep in mind that COVID-19 information…
More Evidence Links Epstein-Barr Virus to MS
More support has been added to the belief that a link exists between the Epstein-Barr virus (EBV) and multiple sclerosis…
MS News that Caught My Eye Last Week: Bafiertam, Stem Cell Transplant Damage, Gilenya Study, NurOwn Benefits
FDA Approves Bafiertam, Tecfidera Bioequivalent, for Relapsing MS This is the second disease-modifying therapy (DMT) OK’d by the FDA…
A Good News Story About an MS Treatment
I love it when a multiple sclerosis treatment works well for someone. It doesn’t matter if that treatment is a…
MS News that Caught My Eye Last Week: Diagnosis by Antibody, Ocrevus After 6 Years, Telemedicine, New DMT Pill
New Nanosensor May Help to Diagnose MS at Early Stages My neurologist likes to say that “brain is time.”…
How Has COVID-19 Affected Your MS Life?
I canceled my April blood draw. The protocol for Lemtrada (alemtuzumab) requires lab work each month because the treatment can…
News that Caught My Eye Last Week: Ocrevus Infusion Time, Monocytes as a Therapy Target, MS and Work
Shorter Ocrevus Infusion Time Up for Approval in US and Europe One of the drawbacks to infusion therapies is…
COVID-19, Joey Cocker, and Me
It’s comforting to have this guy, with his floppy ears, stretched out next to me as I sit here writing.
MS News that Caught My Eye Last Week: Fampyra, COVID-19, Vitamin D, Neurodegeneration
Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland I used Ampyra, as Fampyra is known in the…
A Snapshot of COVID-19 and Disease-modifying Therapies
Are people with MS more susceptible than the average person to the coronavirus that causes COVID-19? And if COVID-19 attacks…
MS News that Caught My Eye Last Week: COVID-19 Database, ATA188 Trial Postponed, Teen Smoking, Myelin and Fruit Peels
New Database to Compile COVID-19 Data About People with MS and Related Diseases There are databases in the U.K.
My Lemtrada Journey, 2 Years After My Second Round
Happy Lemtrada anniversary to me! It’s been two years since I completed my second round of Lemtrada (alemtuzumab) infusions, and…
MS News that Caught My Eye Last Week: Exercise, Diet, and Myelin
Regular Exercise ‘Strongly Recommended’ to Ease Fatigue in MS This may seem like a no-brainer. But once upon a…